于军辉,金 岚,王 今.循环肿瘤细胞对Ⅱ期结直肠癌根治术预后的预测价值73例分析[J].中国肿瘤,2020,29(3):230-234.
循环肿瘤细胞对Ⅱ期结直肠癌根治术预后的预测价值73例分析
Prognostic Value of Circulating Tumor Cells in Stage Ⅱ Colorectal Cancer Undergoing Curative Resection:Seventy-three Cases Report
中文关键词  修订日期:2019-11-10
DOI:10.11735/j.issn.1004-0242.2020.03.A012
中文关键词:  循环肿瘤细胞  结直肠癌  辅助化疗  预后因素
英文关键词:circulating tumor cell  colorectal cancer  adjuvant chemotherapy  prognostic factor
基金项目:国家科技支撑计划资助项目国家科技支撑计划课题(2015BAI13B09);北京市医管局临床医学发展专项经费资助项目(ZYLX201504);北京市卫生系统高层次卫生技术人才培养计划(2015-3-005)
作者单位
于军辉 首都医科大学附属北京世纪坛医院 
金 岚 首都医科大学附属北京友谊医院国家消化系统疾病临床医学研究中心 
王 今 首都医科大学附属北京友谊医院国家消化系统疾病临床医学研究中心 
摘要点击次数: 1648
全文下载次数: 251
中文摘要:
      摘 要:[目的]阐明循环肿瘤细胞(CTC)在Ⅱ期结直肠癌(CRC)患者根治术预后的预测作用。[方法] 采集73例Ⅱ期CRC患者静脉血,应用阴离子富集和免疫荧光原位杂交法(imFISH)鉴定CTC。并对73例患者的临床病理特征和无复发生存期(RFS)进行分析。[结果] Ⅱ期CRC患者的CTC总阳性率为65.8%。无复发与复发患者CTC阳性率分别为62.7%和87.5%。平均RFS为42.6个月,CTC阳性者vs CTC阴性者平均RFS分别为40.7个月vs 46.0个月(P=0.043)。CTC阳性并且行辅助化疗患者未出现复发,而CTC阳性未行辅助化疗患者平均RFS为45.8个月。[结论] CTC可用作预测Ⅱ期CRC患者平均RFS的预后因素,并有可能筛选出可以进行辅助化疗的Ⅱ期CRC患者。
英文摘要:
      Abstract:[Purpose]To clarify the role of circulating tumor cell(CTC) in stage Ⅱ colorectal cancer(CRC) patients treated with curative surgery. [Methods] CTCs were detected using a negative enrichment and immuno-fluorescence in situ hybridization (imFISH) staining method from the venous blood samples obtained from 73 stage Ⅱ CRC patients. The clinic-pathologic characteristics and recurrence free survival(RFS) were collected. [Results]73 stage Ⅱ CRC patients were included in this study. The CTC positive rate was 65.8% in all patients,62.7% in no recurrence patients and 87.5% in recurrent patients. The average RFS was 42.6 months for all patients,40.7 months for CTC-positive patients,and 46.0 months for CTC-negative patients(P=0.043). No recurrence occurred for CTC-positive patients treated with adjuvant chemotherapy. The average RFS for CTC-positive patients without adjuvant chemotherapy was 45.8 months. [Conclusion] CTC could be used as a prognostic factor to predict average RFS for stage Ⅱ CRC patients,and may have potential in selecting stage Ⅱ CRC patients for adjuvant chemotherapy.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器